# Life Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/life-biosciences-2

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.life-biosciences.com
- Total disclosed funding: $39M
- Latest round: Series A (Apr 10, 2023)
- Investors on record: 7

## About

Established in 2021 and based in Beijing, China, Life Biosciences operates as a scientific research service provider that focuses on laboratory animal. The company established branch offices in Chengdu, Shenzhen, and Jiangsu. It has set up over 5 experimental model resource bases and more than 5 laboratory research service platforms. In April 2023, Life Biosciences raised appeoximately CNY 100 million in series A++ funding led by new investor SDIC Venture Capital. Other returning investors Rongdao (Hainan) Equity Investment Fund Management and Sanya Yazhouwan Venture Capital also participated in the round. The round was part of a larger CNY 270 million series A funding.

The company provides laboratory animal resources and services for clients, such as biomedical enterprises, scientific research institutions and hospitals. The business of the company includes breeding, conservation breeding and import substitution of experimental animals. Lingfu Biotechnology has layout Yangtze River delta experimental beagle dog and marmoset resource base, Hainan experimental cynomolgus monkey and miniature pig animal resource base. The company provides scientific research services including experimental services, testing services, imaging services, foster care and decontamination services and animal behavior analysis services.

In the future, the company will carry out the domestic and international layout of non-human primate (NHP) resource bases and the construction of experimental facilities related to brain science and nervous system disease models.

## Funding rounds

- Series A, Apr 10, 2023, $15M — SDIC Venture Capital, Rongdao (Hainan) Equity Investment Fund Management, Sanya Yazhouwan Venture Capital
- Series A, Dec 29, 2022, $24M — Legend Capital, MSA Capital, Puhua Capital, Beijing Saifu Pharmaceutical Research Institute Co., Ltd., Rongdao (Hainan) Equity Investment Fund Management, Sanya Yazhouwan Venture Capital

## Investors

- Legend Capital — Series A
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series A
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- Beijing Saifu Pharmaceutical Research Institute Co., Ltd. — Series A
- Rongdao (Hainan) Equity Investment Fund Management — Series A
- Sanya Yazhouwan Venture Capital — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A